Introduction / Forbion at a glance
Forbion at a glance
Core metrics demonstrating our expansion, scale, and worldwide impact
2006
Launch year
€5bn
AUM
11
Funds
3
Offices
(Naarden, Munich, Boston)
150+
Institutional investors
75
Active companies
81
Professionals1
(incl. 36 MDs or PhDs)
15
Nationalities
142
Companies financed
since inception
Data as of end of 2025.
Source: Forbion.
1. Including 21 Operating Partners and Venture Partners and 3 fellows.
We use our strong background in both science and business, to support a variety of investments and companies in our field, bringing them successfully to the market.”
Martien van Osch
Managing Partner and Co-Founder
Impacting lives everyday
Behind our investments is a culture that considers the impact on patients and society. We focus on addressing high and unmet medical needs and improving the quality of patients’ lives.
Proven health outcomes driven by scalable scientific innovation
~3.3bn
Addressable patient
population
1.6m+
Patients benefitting from approved
medical products
~13,300
Estimated number of participants
to be enrolled in Clinical Trials
153
Total number of drug programs
at the end of 2025
96
Drug programs & indications
in the clinic2
21
Approved medical products by
former portfolio companies
Data as of end of 2025.
Source: Forbion.
2. 73 unique drug programs, if different indications of the same drug product are not included.
Contributing to the economy
Forbion invests over €5 billion in biotech and sustainable technologies, turning scientific innovation into growing businesses. Our investments create skilled jobs, attract capital, and strengthen the life sciences and BioEconomy.
Our contribution in numbers
2,900+
Jobs supported by Forbion funds
37
Portfolio companies created by
Forbion since its launch
210+
Net new hires by
Forbion companies3
Data as of end of 2025.
Source: Forbion.
3. Includes only new hires by private portfolio companies in 2025.